Weinbren K, Salm R, Greenberg G
Br Med J. 1978 Mar 18;1(6114):683-5. doi: 10.1136/bmj.1.6114.683.
To evaluate the evidence for iron compounds as local carcinogens in man, histological material and clinical reports have been reviewed in seven of the eight published cases of tumours developing at the site of intramuscular injections. The microscopical appearances suggested benign lesions in two cases and a variety of tumours in the other five. In only two cases (a rhabdomyosarcoma and a fibrosarcoma) was the interval between injections and tumour development longer than six years. Of the remaining three tumours, one was considered to be a rather slowly growing haemangiopericytoma (with an interval of two years), one appeared to be a subcutaneous lymphoma with no evidence of having arisen in the gluteal muscles, and one was a pleomorphic sarcoma with a possible five-year interval. Sarcomas induced experimentally by iron compounds differ in being less variable in type and in containing abundant iron-containing macrophages, which were negligible in these human tumours.Although the total number of patients who have received intramuscular injections of iron compounds is not known, the present findings, in contrast to experimental work, do not support the view that such treatment carries a strong risk of tumour development.
为评估铁化合物作为人体局部致癌物的证据，我们回顾了已发表的8例在肌肉注射部位发生肿瘤的病例中的7例的组织学资料和临床报告。显微镜下表现显示，2例为良性病变，另外5例为多种肿瘤。仅2例（1例横纹肌肉瘤和1例纤维肉瘤）注射与肿瘤发生之间的间隔超过6年。其余3例肿瘤中，1例被认为是生长较为缓慢的血管外皮细胞瘤（间隔2年），1例似乎是皮下淋巴瘤，无证据表明起源于臀肌，另1例是多形性肉瘤，可能间隔5年。铁化合物实验诱导的肉瘤在类型上变化较小，且含有丰富的含铁巨噬细胞，而在这些人类肿瘤中含铁巨噬细胞数量可忽略不计。尽管接受铁化合物肌肉注射的患者总数不详，但与实验研究相比，目前的研究结果不支持这种治疗有很大肿瘤发生风险的观点。
